Publications:

AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis.

Nature Communications

Kim, Dae Gyu DG; Choi, Yongseok Y; Lee, Yuno Y; Lim, Semi S; Kong, Jiwon J; Song, JaeHa J; Roh, Younah Y; Harmalkar, Dipesh S DS; Lee, Kwanshik K; Goo, Ja-Il JI; Cho, Hye Young HY; Mushtaq, Ameeq Ul AU; Lee, Jihye J; Park, Song Hwa SH; Kim, Doyeun D; Min, Byung Soh BS; Lee, Kang Young KY; Jeon, Young Ho YH; Lee, Sunkyung S; Lee, Kyeong K; Kim, Sunghoon S

Publication Date: 2022-05-11

Variant appearance in text: KRAS: I36A

PubMed Link: 35546148

Variant Present in the following documents:

• 41467_2022_30149_MOESM1_ESM.pdf

View BVdb publication page

Oncogenic KRAS: Signaling and Drug Resistance.

Cancers

Kim, Hyeon Jin HJ; Lee, Han Na HN; Jeong, Mi Suk MS; Jang, Se Bok SB

Publication Date: 2021-11-09

Variant appearance in text: KRAS: Ile36Ala

PubMed Link: 34830757

Variant Present in the following documents:

• Main text

View BVdb publication page

Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.

Nature Communications

Shin, Seung-Min SM; Choi, Dong-Ki DK; Jung, Keunok K; Bae, Jeomil J; Kim, Ji-Sun JS; Park, Seong-Wook SW; Song, Ki-Hoon KH; Kim, Yong-Sung YS

Publication Date: 2017-05-10

Variant appearance in text: KRAS: I36A

PubMed Link: 28489072

Variant Present in the following documents:

• ncomms15090.pdf

View BVdb publication page